These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35619629)

  • 1. Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report.
    Umihira S; Koyanagi T; Tamura K; Takahashi Y; Yoshiba T; Takahashi S; Taneichi A; Saga Y; Takei Y; Fujiwara H
    Exp Ther Med; 2022 Jun; 23(6):409. PubMed ID: 35619629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.
    Eguchi S; Shinkawa H; Sato Y; Nakai K; Takemura S; Tanaka S; Amano R; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Miyazaki T; Ishihara A; Shirai D; Kubo S
    Clin J Gastroenterol; 2021 Jun; 14(3):858-865. PubMed ID: 33811313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
    Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
    Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced endometrial cancer with multiple immune-related adverse events coinciding with the complete response to radiotherapy after immune checkpoint inhibitor therapy: A case report.
    Tanaka Y; Amano T; Takahashi A; Nishimura H; Yamanaka H; Yoneoka Y; Tsuji S; Murakami T
    Gynecol Oncol Rep; 2023 Oct; 49():101265. PubMed ID: 37705723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
    J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
    Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
    J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer.
    Nagai T; Mogami T; Takeda T; Tomiyama N; Yasui T
    Urol Case Rep; 2021 Nov; 39():101766. PubMed ID: 34285878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.
    Harada T; Uetani N; Inui G; Ishikawa H; Funaki Y; Takata M; Okazaki R; Yamaguchi K; Morita M; Kitatani S; Yamasaki A
    Respir Med Case Rep; 2024; 49():102035. PubMed ID: 38712312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report.
    Alhusari L; Abdallah M; Nwanwene K; Shenouda M
    Cureus; 2024 Mar; 16(3):e55666. PubMed ID: 38586668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer.
    Ing BI; Kuhl D; Glassman D; Johnson CA; Patel S; Jazaeri AA
    Gynecol Oncol Rep; 2023 Dec; 50():101296. PubMed ID: 37920829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab.
    Habib T; Abu-Abaa M; Gandhi N
    Cureus; 2023 Apr; 15(4):e38332. PubMed ID: 37266049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
    Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
    J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.